These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 24608428)

  • 1. Targeting RNA polymerase I to treat MYC-driven cancer.
    Poortinga G; Quinn LM; Hannan RD
    Oncogene; 2015 Jan; 34(4):403-12. PubMed ID: 24608428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Onzin, a c-Myc-repressed target, promotes survival and transformation by modulating the Akt-Mdm2-p53 pathway.
    Rogulski K; Li Y; Rothermund K; Pu L; Watkins S; Yi F; Prochownik EV
    Oncogene; 2005 Nov; 24(51):7524-41. PubMed ID: 16170375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measuring MYC-Mediated Metabolism in Tumorigenesis.
    Tang HY; Goldman AR; Zhang X; Speicher DW; Dang CV
    Methods Mol Biol; 2021; 2318():231-239. PubMed ID: 34019293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MYC regulation of cell growth through control of transcription by RNA polymerases I and III.
    Campbell KJ; White RJ
    Cold Spring Harb Perspect Med; 2014 May; 4(5):. PubMed ID: 24789877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The nucleolus as a fundamental regulator of the p53 response and a new target for cancer therapy.
    Woods SJ; Hannan KM; Pearson RB; Hannan RD
    Biochim Biophys Acta; 2015 Jul; 1849(7):821-9. PubMed ID: 25464032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic MYC Induces the Impaired Ribosome Biogenesis Checkpoint and Stabilizes p53 Independent of Increased Ribosome Content.
    Morcelle C; Menoyo S; Morón-Duran FD; Tauler A; Kozma SC; Thomas G; Gentilella A
    Cancer Res; 2019 Sep; 79(17):4348-4359. PubMed ID: 31292158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.
    Rebello RJ; Kusnadi E; Cameron DP; Pearson HB; Lesmana A; Devlin JR; Drygin D; Clark AK; Porter L; Pedersen J; Sandhu S; Risbridger GP; Pearson RB; Hannan RD; Furic L
    Clin Cancer Res; 2016 Nov; 22(22):5539-5552. PubMed ID: 27486174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ARF tumor suppressor: keeping Myc on a leash.
    Gregory MA; Qi Y; Hann SR
    Cell Cycle; 2005 Feb; 4(2):249-52. PubMed ID: 15655352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ribosome biogenesis surveillance: probing the ribosomal protein-Mdm2-p53 pathway.
    Deisenroth C; Zhang Y
    Oncogene; 2010 Jul; 29(30):4253-60. PubMed ID: 20498634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AKT promotes rRNA synthesis and cooperates with c-MYC to stimulate ribosome biogenesis in cancer.
    Chan JC; Hannan KM; Riddell K; Ng PY; Peck A; Lee RS; Hung S; Astle MV; Bywater M; Wall M; Poortinga G; Jastrzebski K; Sheppard KE; Hemmings BA; Hall MN; Johnstone RW; McArthur GA; Hannan RD; Pearson RB
    Sci Signal; 2011 Aug; 4(188):ra56. PubMed ID: 21878679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MYC and the control of apoptosis.
    McMahon SB
    Cold Spring Harb Perspect Med; 2014 Jul; 4(7):a014407. PubMed ID: 24985130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myc's secret life without Max.
    Gallant P; Steiger D
    Cell Cycle; 2009 Dec; 8(23):3848-53. PubMed ID: 19887915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MYC regulates ribosome biogenesis and mitochondrial gene expression programs through its interaction with host cell factor-1.
    Popay TM; Wang J; Adams CM; Howard GC; Codreanu SG; Sherrod SD; McLean JA; Thomas LR; Lorey SL; Machida YJ; Weissmiller AM; Eischen CM; Liu Q; Tansey WP
    Elife; 2021 Jan; 10():. PubMed ID: 33416496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma.
    Devlin JR; Hannan KM; Hein N; Cullinane C; Kusnadi E; Ng PY; George AJ; Shortt J; Bywater MJ; Poortinga G; Sanij E; Kang J; Drygin D; O'Brien S; Johnstone RW; McArthur GA; Hannan RD; Pearson RB
    Cancer Discov; 2016 Jan; 6(1):59-70. PubMed ID: 26490423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myc as a Regulator of Ribosome Biogenesis and Cell Competition: A Link to Cancer.
    Destefanis F; Manara V; Bellosta P
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32516899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MYC-Driven Neuroblastomas Are Addicted to a Telomerase-Independent Function of Dyskerin.
    O'Brien R; Tran SL; Maritz MF; Liu B; Kong CF; Purgato S; Yang C; Murray J; Russell AJ; Flemming CL; von Jonquieres G; Pickett HA; London WB; Haber M; Gunaratne PH; Norris MD; Perini G; Fletcher JI; MacKenzie KL
    Cancer Res; 2016 Jun; 76(12):3604-17. PubMed ID: 27197171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myc's broad reach.
    Eilers M; Eisenman RN
    Genes Dev; 2008 Oct; 22(20):2755-66. PubMed ID: 18923074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nucleophosmin is essential for c-Myc nucleolar localization and c-Myc-mediated rDNA transcription.
    Li Z; Hann SR
    Oncogene; 2013 Apr; 32(15):1988-94. PubMed ID: 22665062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting MYC in cancer therapy: RNA processing offers new opportunities.
    Koh CM; Sabò A; Guccione E
    Bioessays; 2016 Mar; 38(3):266-75. PubMed ID: 26778668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNA polymerases I and III, growth control and cancer.
    White RJ
    Nat Rev Mol Cell Biol; 2005 Jan; 6(1):69-78. PubMed ID: 15688068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.